HROW - Harrow Health, Inc.
| Previous Close | 6.99 |
| Open | 6.96 |
| Bid | 6.95 x 1000 |
| Ask | 6.94 x 1000 |
| Day's Range | 6.74 - 7.05 |
| 52 Week Range | 4.10 - 8.99 |
| Volume | 101,884 |
| Avg. Volume | 162,733 |
| Market Cap | 176.714M |
| Beta (5Y Monthly) | 0.23 |
| PE Ratio (TTM) | 12.08 |
| EPS (TTM) | 0.58 |
| Earnings Date | Mar 09, 2020 - Mar 15, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.38 |
- Insider Monkey
Is Harrow Health, Inc. (HROW) A Good Stock To Buy?
Is Harrow Health, Inc. (NASDAQ:HROW) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after […]
- Simply Wall St.
The Harrow Health (NASDAQ:HROW) Share Price Is Up 256% And Shareholders Are Boasting About It
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
- PR Newswire
Inventor Of "LessDrops," Surgical Eyedrop, Wins Return Of Patent From Harrow Health
Novel Drug Solutions, LLC and Eye Care Northwest, PA, announce the return of their unrestricted patent rights to several awarded and pending USA and international patents previously controlled by Harrow Health, Inc. (NASDAQ: HROW formerly known as Imprimis Pharmaceuticals, Inc.).
- GlobeNewswire
ImprimisRx’s FDA-Registered Outsourcing Facility Issued California License
ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health, Inc. (HROW), announced that on December 9, 2019, its FDA-registered 503B outsourcing facility received a non-resident operating license and has now begun shipping into California. This license allows California-based ophthalmologists, optometrists, surgery centers and hospitals to efficiently order and stock ImprimisRx’s more than 40 ophthalmic products for on-demand administration to their patients.
- Zacks
Harrow Health (HROW) Reports Q3 Loss, Misses Revenue Estimates
Harrow (HROW) delivered earnings and revenue surprises of -2.27% and -4.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Harrow Health Publishes Third Quarter Letter to Stockholders
NASHVILLE, Tenn., Nov. 13, 2019 -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the third quarter 2019. Please click here to review Harrow Health’s.
- Zacks
Earnings Preview: Harrow Health (HROW) Q3 Earnings Expected to Decline
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- American City Business Journals
Publicly traded health care company signs lease for Green Hills headquarters
The new office will be the first physical footprint the company has made in Music City since it announced it was moving its headquarters from San Diego to Nashville in June.
- Simply Wall St.
Is Harrow Health (NASDAQ:HROW) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
- GlobeNewswire
Harrow Health to Announce Third Quarter 2019 Financial Results on November 13, 2019
Harrow Health, Inc. (HROW) today announced that after the close of trading on Wednesday, November 13, 2019, it will release third quarter 2019 financial results and host a conference call at 5:00 p.m. Eastern Standard Time / 2:00 p.m. Pacific Standard Time to discuss the financial results and recent business developments. After the close of the market on November 13, 2019, Harrow will issue a press release containing relevant financial results and a link to a Letter to Shareholders.
- GlobeNewswire
Solas BioVentures Co-Founder David Adair, M.D. Joins Mayfield Pharmaceuticals Board of Directors
Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (HROW), today announced David Adair, M.D. will join the Mayfield Pharmaceuticals Board of Directors. Dr. Adair is a Co-Founder and Managing Director of Solas BioVentures, a venture capital fund that invests exclusively in the Life Sciences industry. Dr. Adair has extensive experience serving as a director on the boards of several pharmaceutical and medical device companies, including companies specializing in women’s health, in addition to 21 years as an OB/GYN Department Professor and Vice Chairman at the University of Tennessee College of Medicine in Chattanooga.
- GlobeNewswire
Mayfield Pharmaceuticals to Present at the SVB Leerink New Treatments Focused on Women’s Health Conference on October 10, 2019
BOSTON, Oct. 08, 2019 -- Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its Chief Executive Officer,.
- GlobeNewswire
ImprimisRx to Focus on Investments in Quality at the 2019 American Academy of Ophthalmology Meeting
ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health, Inc. (HROW), today announced its participation at the upcoming 2019 American Academy of Ophthalmology (AAO) Annual Meeting to be held at the Moscone Center in San Francisco, CA, October 12-15. The American Academy of Ophthalmology is the world’s largest association of eye physicians and surgeons, encompassing a community of 32,000 medical doctors. As an FDA-registered and FDA-inspected outsourcing facility, ImprimisRx has made and continues to make significant investments in equipment, processes and personnel to comply with these standards.
- Simply Wall St.
Harrow Health, Inc. (NASDAQ:HROW) Delivered A Better ROE Than Its Industry
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
- Zacks
The Zacks Analyst Blog Highlights: Air Industries, Chuy's, CNX Midstream Partners, Hibbett Sports and Harrow Health
The Zacks Analyst Blog Highlights: Air Industries, Chuy's, CNX Midstream Partners, Hibbett Sports and Harrow Health
- Zacks
5 Best Stocks to Buy on Dollar's Newfound Strength
Small caps, being U.S.-centric, are better poised to weather a stronger US dollar. This category is cushioned against the loss of competitiveness and impact of a stronger greenback.
- GlobeNewswire
Harrow Health to Attend Lake Street’s 3rd Annual Best Ideas Growth Conference September 12, 2019
Harrow Health, Inc. (HROW) today announced that it will be attending Lake Street’s 3rd Annual BIG Conference September 12, 2019. Please contact your Lake Street representative to arrange a meeting. Alternatively, to receive additional information, request an invitation or to schedule a one-on-one meeting, you may also email conference@lakestreetcm.com or call 612-326-1305. Founded in 2012, Lake Street Capital Markets is a full-service boutique investment bank focused on dynamic high-growth companies and sectors of the economy.
- Zacks
Harrow Health Enters Oversold Territory
Harrow Health has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- Simply Wall St.
Does Harrow Health, Inc.'s (NASDAQ:HROW) CEO Pay Matter?
In 2012 Mark Baum was appointed CEO of Harrow Health, Inc. (NASDAQ:HROW). First, this article will compare CEO...
- Zacks
Harrow Health (HROW) Reports Q2 Loss, Tops Revenue Estimates
Harrow (HROW) delivered earnings and revenue surprises of -50.00% and 7.67%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Harrow Health Announces Second Quarter 2019 Results
NASHVILLE, Tenn., Aug. 14, 2019 -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the second quarter 2019. Second Quarter 2019 and Other Recent Notable.
- Zacks
Analysts Estimate Harrow Health (HROW) to Report a Decline in Earnings: What to Look Out for
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Harrow Health Forms Stowe Pharmaceuticals Subsidiary to Develop Broad Spectrum Anti-Microbial Ophthalmic and Otic Therapeutics
NASHVILLE, Tenn., Aug. 02, 2019 -- Harrow Health, Inc. (NASDAQ: HROW) today announced that its newly formed subsidiary, Stowe Pharmaceuticals, Inc., has entered into an.
- GlobeNewswire
Harrow Health Announces Launch of Mayfield Pharmaceuticals
NASHVILLE, Tenn., July 31, 2019 -- Harrow Health, Inc. (NASDAQ: HROW), today announced it has filed a Form 8-K with the Securities and Exchange Commission containing a.
